TIGIT
Immune checkpoint inhibitors
Melanoma
Microbiome
NK cells
Random Forest
Response
TIGIT
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
29
07
2023
accepted:
20
10
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Composition of the intestinal microbiota has been correlated to therapeutic efficacy of immune checkpoint inhibitors (ICI) in various cancer entities including melanoma. Prediction of the outcome of such therapy, however, is still unavailable. This prospective, non-interventional study was conducted in order to achieve an integrated assessment of the connection between a specific intestinal microbiota profile and antitumor immune response to immune checkpoint inhibitor therapy (anti-PD-1 and/or anti-CTLA-4) in melanoma patients. We assessed blood and stool samples of 29 cutaneous melanoma patients who received immune checkpoint inhibitor therapy. For functional and phenotypical immune analysis, 12-color flow cytometry and FluoroSpot assays were conducted. Gut microbiome was analyzed with shotgun metagenomics sequencing. To combine clinical, microbiome and immune variables, we applied the Random Forest algorithm. A total of 29 patients was analyzed in this study, among whom 51.7% (n = 15) reached a durable clinical benefit. The Immune receptor TIGIT is significantly upregulated in T cells (p = 0.0139) and CD56 Our results reconfirm a link between intestinal microbiota and response to ICI therapy in melanoma patients and furthermore point to TIGIT as a promising target for future immunotherapies.
Sections du résumé
BACKGROUND
BACKGROUND
Composition of the intestinal microbiota has been correlated to therapeutic efficacy of immune checkpoint inhibitors (ICI) in various cancer entities including melanoma. Prediction of the outcome of such therapy, however, is still unavailable. This prospective, non-interventional study was conducted in order to achieve an integrated assessment of the connection between a specific intestinal microbiota profile and antitumor immune response to immune checkpoint inhibitor therapy (anti-PD-1 and/or anti-CTLA-4) in melanoma patients.
METHODS
METHODS
We assessed blood and stool samples of 29 cutaneous melanoma patients who received immune checkpoint inhibitor therapy. For functional and phenotypical immune analysis, 12-color flow cytometry and FluoroSpot assays were conducted. Gut microbiome was analyzed with shotgun metagenomics sequencing. To combine clinical, microbiome and immune variables, we applied the Random Forest algorithm.
RESULTS
RESULTS
A total of 29 patients was analyzed in this study, among whom 51.7% (n = 15) reached a durable clinical benefit. The Immune receptor TIGIT is significantly upregulated in T cells (p = 0.0139) and CD56
CONCLUSIONS
CONCLUSIONS
Our results reconfirm a link between intestinal microbiota and response to ICI therapy in melanoma patients and furthermore point to TIGIT as a promising target for future immunotherapies.
Identifiants
pubmed: 38017389
doi: 10.1186/s12885-023-11551-5
pii: 10.1186/s12885-023-11551-5
pmc: PMC10685659
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
TIGIT protein, human
0
Receptors, Immunologic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1160Subventions
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Organisme : Deutsche Krebshilfe
ID : 70112696
Informations de copyright
© 2023. The Author(s).
Références
Mucosal Immunol. 2017 Jan;10(1):18-26
pubmed: 27554295
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Med. 2022 Apr;28(4):690-703
pubmed: 35440726
Elife. 2021 May 04;10:
pubmed: 33944776
JCI Insight. 2020 Dec 3;5(23):
pubmed: 33268597
J Clin Invest. 2015 May;125(5):2046-58
pubmed: 25866972
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Immunol. 2006 Jul 15;177(2):1052-61
pubmed: 16818761
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Sci Adv. 2023 Jan 27;9(4):eadd8977
pubmed: 36706185
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Immunity. 2015 Feb 17;42(2):344-355
pubmed: 25680274
Gut. 2019 Mar;68(3):385-388
pubmed: 30530851
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Science. 2021 Dec 24;374(6575):1632-1640
pubmed: 34941392
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
J Med Virol. 2022 Dec;94(12):6047-6059
pubmed: 36000446
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Nat Med. 2022 Mar;28(3):535-544
pubmed: 35228751
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Nat Biotechnol. 2023 Nov;41(11):1633-1644
pubmed: 36823356
Nat Rev Gastroenterol Hepatol. 2022 Sep;19(9):565-584
pubmed: 35468952
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Front Immunol. 2021 Jul 22;12:699895
pubmed: 34367161
Science. 2013 Nov 22;342(6161):971-6
pubmed: 24264990
Front Microbiol. 2020 Feb 11;11:120
pubmed: 32117143
Ann Oncol. 2017 Jun 01;28(6):1368-1379
pubmed: 28368458
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Int J Mol Sci. 2020 Nov 07;21(21):
pubmed: 33171792
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Neoplasia. 2017 Oct;19(10):848-855
pubmed: 28923537
Cancer Cell. 2014 Dec 8;26(6):923-937
pubmed: 25465800